Rabacfosadine (Tanovea) for the Treatment of Relapsed Multicentric Canine Lymphoma
1Colorado State University, Fort Collins, CO, USA; 2Hope Veterinary Specialists, Blue Pearl, Malvern, PA, USA; 3FidoCure, Inc., Palo Alto, CA, USA; 4University of Georgia, Athens, GA, USA; 5University of Wisconsin-Madison, Madison, WI, USA; 6Southwest Veterinary Oncology, Tucson, AZ, USA; 7Veterinary Specialty Hospital of San Diego, Sorrento Valley, CA, USA; 8University of California-Davis, Davis, CA, USA; 9Veterinary Cancer Group, Tustin, CA, USA; 10Oregon State University, Corvallis, OR, USA; 11University of Illinois, Urbana, IL, USA; 12VCA Katonah-Bedford Veterinary Center, Bedford Hills, NY, USA
Introduction
The aim of this study was to evaluate the efficacy and adverse event profile of rabacfosadine for the treatment of relapsed multicentric canine lymphoma. Previous studies evaluating rabacfosadine for relapsed lymphoma have assessed selected patient populations, various doses, or with additional treatments. Therefore, data evaluating a larger number of dogs receiving standard doses of single-agent rabacfosadine in the relapse setting is needed.
Methods
This was a single arm, open-label, multi-institutional prospective trial. Dogs received rabacfosadine at 1.0 mg/kg every 21 days for up to five treatments. Response was assessed via VCOG-CTCAE criteria, and the progression free interval (PFI) was calculated by the Kaplan-Meier method. The effect of variables on PFI and overall response rate (ORR) was evaluated. Adverse events (AEs) were summarized.
Results
One hundred and fifty-nine dogs were evaluated. Most dogs were heavily pre-treated (70% received >2 previous protocols). The ORR was 46% (20% CR, 26% PR). Immunophenotype, substage, and degree of pre-treatment were significantly associated with PFI. Responders (CR or PR) had a significantly longer median PFI than non-responders (118 days and 63 days for CR and PR, respectively, vs. 21 days for NR). Immunophenotype and degree of pre-treatment were significantly associated with response (ORR=67% for dogs with B cell lymphoma at first relapse). AEs were similar to those reported in other studies.
Conclusion
These data confirm the efficacy of rabacfosadine in the relapse setting and affirm improved efficacy in less heavily pre-treated patients with B cell disease.
Funding Information
This study was sponsored by VetDC, Elanco, and the FDA (grant # 1R01 FD006323-01).